Pettersson Birgitta, Almer Sven, Albertioni Freidoun, Söderhäll Stefan, Peterson Curt
Department of Clinical Pharmacology, University Hospital, SE-58185 Linköping, Sweden.
Ther Drug Monit. 2002 Jun;24(3):351-8. doi: 10.1097/00007691-200206000-00005.
This study examined the role of thiopurine methyltransferase (TPMT) polymorphism in the metabolism and clinical effects of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease and childhood leukemia. The current hypothesis is that the cytotoxic effects of thiopurines are caused by the incorporation of thioguanine nucleotides into DNA. In this context, S-methylation catalyzed by TPMT can be regarded as a competing metabolic pathway. The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children). The concentrations of thioguanine nucleotides and methylthioinosine monophosphate were also assayed in red blood cells from the patients. The TPMT activity and the concentrations of methylthioinosine monophosphate and thioguanine nucleotides were higher in children than in adults. All children but no adult patient received concomitant methotrexate. Interaction between methotrexate and 6-mercaptopurine has been described, and may explain the results. Low TPMT activity in adult patients with inflammatory bowel disease correlated to an increased incidence of adverse drug reactions. However, there was no correlation between TPMT activity and the red blood cell concentrations of methylthioinosine monophosphate or thioguanine nucleotides, or between the concentrations of these metabolites and the occurrence of adverse effects. The results show that the role of thiopurine metabolism for drug effects is complex.
本研究探讨了硫嘌呤甲基转移酶(TPMT)基因多态性在硫唑嘌呤和6-巯基嘌呤治疗炎症性肠病和儿童白血病中的代谢及临床效果中的作用。目前的假说是,硫嘌呤的细胞毒性作用是由硫代鸟嘌呤核苷酸掺入DNA所致。在此背景下,TPMT催化的S-甲基化可被视为一条竞争性代谢途径。作者检测了122例接受硫唑嘌呤或6-巯基嘌呤治疗的患者(83例患有炎症性肠病的成年人和39例急性淋巴细胞白血病儿童)以及290例未接受治疗的对照者(219例成年献血者和71例儿童)红细胞中的TPMT活性。还检测了患者红细胞中硫代鸟嘌呤核苷酸和甲基硫代肌苷单磷酸的浓度。儿童的TPMT活性以及甲基硫代肌苷单磷酸和硫代鸟嘌呤核苷酸的浓度均高于成年人。所有儿童均接受了甲氨蝶呤联合治疗,而成年患者均未接受。甲氨蝶呤与6-巯基嘌呤之间的相互作用已有报道,这可能解释了研究结果。炎症性肠病成年患者中TPMT活性较低与药物不良反应发生率增加相关。然而,TPMT活性与红细胞中甲基硫代肌苷单磷酸或硫代鸟嘌呤核苷酸的浓度之间,以及这些代谢物的浓度与不良反应的发生之间均无相关性。结果表明,硫嘌呤代谢对药物效应的作用较为复杂。